Targeted Mass Azithromycin Distribution for Trachoma: A Community-Randomized Trial (TANA II).

Background Current guidelines recommend annual community-wide mass administration of azithromycin for trachoma. Targeting treatments to those most likely to be infected could reduce the amount of unnecessary antibiotics distributed. Methods In a cluster-randomized trial conducted from 1 November 2010 through 8 November 2013, 48 Ethiopian communities previously treated with annual mass azithromycin distributions for trachoma were randomized in equal numbers to (1) annual azithromycin distributions targeted to children aged 0–5 years, (2) annual azithromycin distributions targeted to households with a child aged 0–5 years found to have clinically active trachoma, (3) continued annual mass azithromycin distributions to the entire community, or (4) cessation of treatment. The primary outcome was the community prevalence of ocular chlamydia infection among children aged 0–9 years at month 36. Laboratory personnel were masked to treatment allocation. Results The prevalence of ocular chlamydia infection among children aged 0–9 years increased from 4.3% (95% confidence interval [CI],.9%–8.6%) at baseline to 8.7% (95% CI, 4.2%–13.9%) at month 36 in the age-targeted arm, and from 2.8% (95% CI,.8%–5.3%) at baseline to 6.3% (95% CI, 2.9%–10.6%) at month 36 in the household-targeted arm. After adjusting for baseline chlamydia prevalence, the 36-month prevalence of ocular chlamydia was 2.4 percentage points greater in the age-targeted group (95% CI, −4.8% to 9.6%; P =.50; prespecified primary analysis). No adverse events were reported. Conclusions Targeting azithromycin treatment to preschool children was no different than targeting azithromycin to households with a child with clinically active trachoma. Neither approach reduced ocular chlamydia over the 3-year study. Clinical Trials Registration NCT01202331. [ABSTRACT FROM AUTHOR]